Latest Thalidomide Stories
Results from Phase 2 Clinical Trials of Carfilzomib in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Featured in Oral Presentations SOUTH SAN FRANCISCO, May 15 /PRNewswire/ -- Proteolix, Inc.
Scientists studying how marine bacteria move have discovered that a sharp variation in water current segregates right-handed bacteria from their left-handed brethren, impelling the microbes in opposite directions.
Thalidomide victims once snubbed by the German government are being offered compensation for birth defects caused by the drug, officials say. The German family ministry has announced it will temporarily waive a 26-year-old ban on considering thalidomide relief claims from foreign countries until the end of 2010, thus enabling victims from around the world to collect damages on the drug formerly made by the German company Grunenthal, The Sunday Times of London reported. Germany since 1983 has...
New subset analysis of bortezomib-relapsed patient population demonstrates 55% overall response rate and extended time to progression NEW YORK, Feb. 26 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
Thalidomide victims in Britain say the government is denying them financial aid as they age and their health worsens. It's estimated more than 450 people whose mothers took thalidomide during pregnancy are nearing 50 and suffering physical breakdowns, The Sunday Times of London reported. Thousands of British mothers were prescribed thalidomide as a cure for morning sickness, and gave birth to babies who then died or grew up with drastically stunted arms and fingers and no shoulder joints....
SOUTH SAN FRANCISCO, Calif., Dec. 9 /PRNewswire/ -- Proteolix, Inc. today announced positive clinical data demonstrating that the company's lead product, carfilzomib, has single-agent activity and promotes durable responses in patients with relapsed and refractory multiple myeloma.
ROCKVILLE, Md., Dec.
SAN FRANCISCO, Dec.
The International Myeloma Foundation (IMF)--supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians--today called for all patients to have access to the newest pharmaceuticals making life-changing advances in the treatment of myeloma.
Revlimid has become the latest in a series of oncology drugs that have failed to satisfy NICE's cost-effectiveness criteria. As a result, Celgene's drug will not be available to multiple myeloma patients on the UK's National Health Service.
- To say in too many words; to express verbosely.
- To express in too many words: sometimes used reflexively.
- The leading idea or a repeated phrase, as of a song or ballad; the refrain; burden.